L. Michael Glodé, M.D. Professor Education: Washington University SOM St. Louis, MO – 1972 University of Colorado Denver School of Medicine Division of Medical Oncology Tel: (303) 724-3853 Fax: (303) 724-3889 e-mail: mike.glode@uchsc.edu Bio Dr. Glodé was the first board-certified Medical Oncologist at the University of Colorado, joining the faculty after training at Dana-Farber Cancer Institute. Research Dr. Glodé's research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to it’s approval and subsequently developed a “single shot” castration agent that is in animal trials. He has also led efforts to evaluate a natural product, silibinin as a preventive or therapeutic agent and has been an investigator on more than 30 clinical trials, including the PI position for the largest adjuvant trial in prostate cancer, SWOG 9921. He has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists” as well as serving as Founding Editor of the ASCO website, www.asco.org.

FACULTY LIST Lynn Bemis Virginia Borges Paul Bunn David Calverley Ross Camidge Dan Chan Gail Eckhardt Anthony Elias Thomas Flaig Marileila Garcia L. Michael Glode Rene Gonzalez Barb Helfrich Fred Hirsch Christopher Hogan Antonio Jimeno Madeleine Kane Choon-Kee Lee Stephen Leong Wells Messersmith Han Myint Ana Oton Peter Raich William Robinson Pepper Schedin John Tentler William Tse Colin Weekes

Publications
Flaig TW, Gustafson DL, Su L, Zirrolli J, Harrison G, Pierson AS, Agarwal R, and Glodé LM:  A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer.  Investigational New Drugs Apr;25(2):139-46. Epub 2006 Nov 1, 2007

L.M. Glodé and M. Lindquist:  The case for adjuvant therapy of prostate cancer, Prostate Cancer Supplement, J. Urol. S30-3, 2006.

Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, and Crawford ED:  Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.  Oncol. Rep. 16(4): 807-810, 2006

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, and Glodé LM: Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the GnRH receptor.  Cancer Research 64: 2090-2095, 2004

Hardy PA, Mazzini MJ, Schweitzer C, Lundstrom K and Glodé LM:  Recombinant Semliki Forest Virus infects and kills human prostate cancer cell lines and prostatic duct epithelial cells ex vivo.  International Journal of Molecular Medicine 5:241-245, 2000

Funding
NIH
Pfizer
Bristol-Myers Squibb
Cell Genesis
Dendreon

PubMed articles

BACK TO TOP